Can GW’s Cannabis Drug Epidiolex Trump Retail CBD Products?

Multi-billion dollar cannabis drug company GW Pharmaceuticals is set to launch its Epidiolex drug in five European countries after a successful first quarter of sales in the U.S.

The U.K.-based company has also cheered investors by announcing successful trials of the CBD isolate drug for patients suffering from a rare epileptic condition. And, concerns that Epidiolex prescriptions could be curtailed by competition from cheaper, off-the-shelf CBD products, have been dismissed by a leading analyst.

During the first quarter, which ended March 31, GW brought in $39.2 million in revenue, it reported in results to the Nasdaq. Epidiolex, which is the first medicine derived entirely from the cannabis plant to gain Food and Drug Administration approval, generated $33.5 million of that in the U.S. It was also recently approved for clinical trials in Japan.

Positive epilepsy trial result

It is used for the treatment of epileptic seizures associated

... read more at: